Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis

Sameer A Parikh, Paolo Strati, Mazie Tsang, Colin Patrick West, Tait D. Shanafelt

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Since the first description of the natural history of chronic lymphocytic leukemia (CLL) by David Galton in 1966, the considerable heterogeneity in the disease course has been well recognized. The Rai and Binetstagingsystemsdescribed ∼40years ago have proven to be robust prognostic tools. Over the past 2 decades, several novel biological, genetic, and molecular markers have been shown to be useful adjuncts to the Rai and Binet staging systems. In this systematic review, we examined the role of immunoglobulin heavy-chain variable region gene (IGHV) mutation status and genetic abnormalities determined by interphase fluorescence in situ hybridization (FISH) in patients with newly diagnosed CLL. The cumulative evidence presented in this systematic review is sufficient to recommend that FISH and IGHV be performed as standard clinical tests for all patients with newly diagnosed CLL in those countries with the resources to do so. In addition to clinical stage, these parameters could represent the minimal standard initial prognostic evaluation for patients with CLL. This approach will allow the application of powerful, recently developed prognostic indices (all of which are dependent on IGHV and FISH results) to all patients with newly diagnosed CLL.

Original languageEnglish (US)
Pages (from-to)1752-1760
Number of pages9
JournalBlood
Volume127
Issue number14
DOIs
StatePublished - Apr 7 2016

Fingerprint

Immunoglobulin Heavy Chains
B-Cell Chronic Lymphocytic Leukemia
Fluorescence In Situ Hybridization
Meta-Analysis
Genes
Fluorescence
Testing
Interphase
Genetic Markers
Mutation

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. / Parikh, Sameer A; Strati, Paolo; Tsang, Mazie; West, Colin Patrick; Shanafelt, Tait D.

In: Blood, Vol. 127, No. 14, 07.04.2016, p. 1752-1760.

Research output: Contribution to journalArticle

Parikh, Sameer A ; Strati, Paolo ; Tsang, Mazie ; West, Colin Patrick ; Shanafelt, Tait D. / Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. In: Blood. 2016 ; Vol. 127, No. 14. pp. 1752-1760.
@article{d2c488ee923445339eb68b33b961cd72,
title = "Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis",
abstract = "Since the first description of the natural history of chronic lymphocytic leukemia (CLL) by David Galton in 1966, the considerable heterogeneity in the disease course has been well recognized. The Rai and Binetstagingsystemsdescribed ∼40years ago have proven to be robust prognostic tools. Over the past 2 decades, several novel biological, genetic, and molecular markers have been shown to be useful adjuncts to the Rai and Binet staging systems. In this systematic review, we examined the role of immunoglobulin heavy-chain variable region gene (IGHV) mutation status and genetic abnormalities determined by interphase fluorescence in situ hybridization (FISH) in patients with newly diagnosed CLL. The cumulative evidence presented in this systematic review is sufficient to recommend that FISH and IGHV be performed as standard clinical tests for all patients with newly diagnosed CLL in those countries with the resources to do so. In addition to clinical stage, these parameters could represent the minimal standard initial prognostic evaluation for patients with CLL. This approach will allow the application of powerful, recently developed prognostic indices (all of which are dependent on IGHV and FISH results) to all patients with newly diagnosed CLL.",
author = "Parikh, {Sameer A} and Paolo Strati and Mazie Tsang and West, {Colin Patrick} and Shanafelt, {Tait D.}",
year = "2016",
month = "4",
day = "7",
doi = "10.1182/blood-2015-10-620864",
language = "English (US)",
volume = "127",
pages = "1752--1760",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "14",

}

TY - JOUR

T1 - Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis

AU - Parikh, Sameer A

AU - Strati, Paolo

AU - Tsang, Mazie

AU - West, Colin Patrick

AU - Shanafelt, Tait D.

PY - 2016/4/7

Y1 - 2016/4/7

N2 - Since the first description of the natural history of chronic lymphocytic leukemia (CLL) by David Galton in 1966, the considerable heterogeneity in the disease course has been well recognized. The Rai and Binetstagingsystemsdescribed ∼40years ago have proven to be robust prognostic tools. Over the past 2 decades, several novel biological, genetic, and molecular markers have been shown to be useful adjuncts to the Rai and Binet staging systems. In this systematic review, we examined the role of immunoglobulin heavy-chain variable region gene (IGHV) mutation status and genetic abnormalities determined by interphase fluorescence in situ hybridization (FISH) in patients with newly diagnosed CLL. The cumulative evidence presented in this systematic review is sufficient to recommend that FISH and IGHV be performed as standard clinical tests for all patients with newly diagnosed CLL in those countries with the resources to do so. In addition to clinical stage, these parameters could represent the minimal standard initial prognostic evaluation for patients with CLL. This approach will allow the application of powerful, recently developed prognostic indices (all of which are dependent on IGHV and FISH results) to all patients with newly diagnosed CLL.

AB - Since the first description of the natural history of chronic lymphocytic leukemia (CLL) by David Galton in 1966, the considerable heterogeneity in the disease course has been well recognized. The Rai and Binetstagingsystemsdescribed ∼40years ago have proven to be robust prognostic tools. Over the past 2 decades, several novel biological, genetic, and molecular markers have been shown to be useful adjuncts to the Rai and Binet staging systems. In this systematic review, we examined the role of immunoglobulin heavy-chain variable region gene (IGHV) mutation status and genetic abnormalities determined by interphase fluorescence in situ hybridization (FISH) in patients with newly diagnosed CLL. The cumulative evidence presented in this systematic review is sufficient to recommend that FISH and IGHV be performed as standard clinical tests for all patients with newly diagnosed CLL in those countries with the resources to do so. In addition to clinical stage, these parameters could represent the minimal standard initial prognostic evaluation for patients with CLL. This approach will allow the application of powerful, recently developed prognostic indices (all of which are dependent on IGHV and FISH results) to all patients with newly diagnosed CLL.

UR - http://www.scopus.com/inward/record.url?scp=84963567600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963567600&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-10-620864

DO - 10.1182/blood-2015-10-620864

M3 - Article

C2 - 26841802

AN - SCOPUS:84963567600

VL - 127

SP - 1752

EP - 1760

JO - Blood

JF - Blood

SN - 0006-4971

IS - 14

ER -